BiovaxID FDA Approval Status

FDA Approved: No
Brand name: BiovaxID
Company: Biovest International, Inc.
Treatment for: Non-Hodgkin's Lymphoma

BiovaxID is a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma.

Development timeline for BiovaxID

Date	Article
Jun 22, 2010	Biovest Announces Mantle Cell Lymphoma as Next Target Indication for Personalized Cancer Vaccine
Jun 5, 2007	Biovest to File for Accelerated Conditional Approval of BiovaxID
Feb 22, 2006	Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID, a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.